The chemotherapy drugs market is expected to experience significant growth due to several factors, including the rising incidence of various cancers and an increase in risk factors associated with cancer development. Additionally, the surge in pharmaceutical trials for chemotherapy drugs and the growing emphasis on enhancing the safety and effectiveness of these treatments are anticipated to drive substantial revenue growth in the market throughout the forecast period (2024–2030). LAS VEGAS , Aug.
22, 2024 /PRNewswire/ -- DelveInsight's Chemotherapy Drugs Market Insights report provides the current and forecast market analysis, individual leading chemotherapy drugs companies' market shares, challenges, chemotherapy drugs market drivers, barriers, trends, and key market chemotherapy drugs companies in the market. Key Takeaways from the Chemotherapy Drugs Market Report As per DelveInsight estimates, North America is anticipated to dominate the global chemotherapy drugs market during the forecast period. Based on the indication segment of the chemotherapy drugs market, the lung cancer category is projected to register a significant growth in revenue in the chemotherapy drugs market during the forecast period (2024–2030).
Notable chemotherapy drugs companies such as Johnson & Johnson Services Inc., Pfizer Inc., GlaxoSmithKline PLC, Eli Lilly and Company, F.
Hoffmann-La Roche Ltd., Novartis AG, Merck & Co. Inc.
, Sanofi S.A., Celgene Corporation, Bristol-Myers Squibb Company, A.